TG Therapeutics Inc (TGTX)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	244,429	244,158	102,537	101,326	100,118	98,908	97,700	96,503	71,135	71,135	68,947	67,249	66,788	—	—	—	7,716	15,074	22,233	29,201
Total stockholders’ equity	US$ in thousands	222,364	192,157	177,568	160,109	160,502	164,769	40,453	27,433	58,587	100,481	129,035	170,386	237,153	311,517	383,130	445,285	519,350	170,658	194,227	-1,353
Debt-to-capital ratio		0.52	0.56	0.37	0.39	0.38	0.38	0.71	0.78	0.55	0.41	0.35	0.28	0.22	0.00	0.00	0.00	0.01	0.08	0.10	1.05

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $244,429K ÷ ($244,429K + $222,364K)
= 0.52

The debt-to-capital ratio of TG Therapeutics Inc has shown fluctuations over the analyzed period. Starting at 1.05 in March 31, 2020, the ratio decreased significantly to 0.01 by December 31, 2020, indicating a substantial reduction in the company's debt relative to its capital. Throughout 2021 and the first half of 2022, the ratio remained at 0.00, signaling a debt-free position or a minimal debt level compared to the total capital.

However, from December 31, 2022, to March 31, 2024, the debt-to-capital ratio saw an upward trend, rising from 0.22 to 0.39. This increase suggests that the company might have taken on more debt relative to its capital during this period. Notably, the ratio peaked at 0.78 on March 31, 2023, indicating a significant increase in debt compared to the company's capital at that point.

Subsequently, by the end of the period on December 31, 2024, the debt-to-capital ratio slightly decreased to 0.52. This suggests that the company's debt level relative to its capital improved compared to the peak in March 31, 2023, but remained higher than some of the previous periods.

In conclusion, while TG Therapeutics Inc experienced fluctuations in its debt-to-capital ratio during the analyzed period, the company demonstrated both decreases and increases in its debt levels relative to its capital, highlighting changes in its financial leverage position over time.